| 王建宇,张莉,高倩,等.丁苯酞注射液治疗急性进展性脑梗死病人的临床疗效及机制研究[J].安徽医药,2022,26(1):179-183. |
| 丁苯酞注射液治疗急性进展性脑梗死病人的临床疗效及机制研究 |
| Clinical efficacy and mechanism of butylphthalide injection in the treatment of patients with acute progressive cerebral infarction |
| |
| DOI：10.3969/j.issn.1009-6469.2022.01.042 |
| 中文关键词: 脑梗死 丁苯酞注射液 同型半胱氨酸 神经因子 炎性因子 凝血功能 |
| 英文关键词: Brain infarction Butylphthalide injection Homocysteine Nerve factors Inflammatory factors Blood coagula-tion function |
| 基金项目: |
|
| 摘要点击次数: 1946 |
| 全文下载次数: 851 |
| 中文摘要: |
| 目的研究丁苯酞注射液用于急性进展性脑梗死病人治疗中的临床疗效其及作用机制。方法选取衡水市人民医院 2018年 1月至 2019年 6月收治的 120例急性进展性脑梗死( APCI)病人纳入本研究，将入选病人均分为传统组与丁苯酞组，传统组给予巴曲酶注射液治疗，丁苯酞组给予巴曲酶注射液联合丁苯酞注射液治疗；治疗 14 d后，评估两组临床疗效，观察用药前后两组病人神经缺损情况、凝血指标、同型半胱氨酸、炎性因子、神经蛋白因子表达水平的变化情况，统计治疗期间不良反应发生率。结果丁苯酞组总有效率 90.00%，传统组总有效率 70.00%，丁苯酞组高于传统组(P<0.05)；用药后，两组病人 D-二聚体( D-D)、纤维蛋白原( FIB)、同型半胱氨酸( Hcy)水平均较组内用药前改善，丁苯酞组均低于传统组［( 122.32±23.20)μg/L比(175.52±22.29)μg/L、(2.81±0.39)g/L比( 3.59±0.44)g/L、(9.23±1.05)μmol/L比( 15.19±1.76)μmol/L，P<0.05］；用药后，两组病人超敏 C反应蛋白( hs-CRP)、肿瘤坏死因子 -α(TNF-α)、白细胞介素 -8(IL-8)水平均较组内用药前降低，丁苯酞组均低于传统组［( 3.43±0.39)mg/L比( 7.06±0.85)mg/L、(16.58±2.44)ng/L比( 25.29±2.60)ng/L、(0.42±0.05)ng/mL比( 0.77±0.10)ng/mL，P<0.05］；用药后，两组病人美国国立卫生研究院卒中量表(NIHSS)评分、 S100蛋白( S100B)、髓鞘碱性蛋白( MBP)、神经元特异性烯醇化酶( NSE)水平均较组内用药前改善，且丁苯酞组均优于传统组( P<0.05)；两组用药期间的不良反应差异无统计学意义( P> |
| 英文摘要: |
| Objective To study the clinical efficacy and mechanism of butylphthalide injection in the treatment of patients with acuteprogressive cerebral infarction.Methods A total of 120 cases of patients with acute progressive cerebral infarction (APCI) admitted toHengshui People's Hospital from January 2018 to June 2019 were enrolled in the study. Patients were divided into traditional group andbutylphthalide group. The traditional group was given batroxobin injection treatment, while the butylphthalide group was given batroxo-bine combined with butylphthalide injection therapy. After 14 days of treatment, the clinical efficacy of the two groups was evaluated, andthe changes of nerve defects, coagulation indexes, expression levels of homocysteine, inflammatory factors and neuroprotein factors beforeand after treatment were observed, and the incidence of adverse reactions during treatment was counted.Results The total effective rate of the butylphthalide group was 90.00%, which was higher than that of the traditional group 70.00%,the difference was statistically signifi-cant (P<0.05); After medication, the levels of D-D, FIB and Hcy in the two groups were improved compared with those before medication,and those in the butylphthalide group were lower than those in the traditional group [traditional group: (175.52±22.29)μg/L, (3.59±0.44)g/L, (15.19±1.76)μmol/L, butylphthalide group:(122.32±23.20)μg/L, (2.81±0.39)g/L, (9.23±1.05)μmol/L], the differences were statisticallysignificant (P<0.05). After treatment, the levels of hS-CRP, TNF-α and IL-8 in the two groups were lower than those before treatment, andthose in the butylphthalide group were lower than those in the traditional group [traditional group: (7.06±0.85)mg/L, (25.29±2.60)ng/L,(0.77±0.10)ng/mL, butylphthalide group: (3.43±0.39)mg/L, (16.58±2.44)ng/L, (0.42±0.05)ng/mL], the differences were statistically sig-nificant (P<0.05). After treatment, NIHSS score, S100B, MBP and NSE levels in the two groups were improved compared with those be-fore treatment, and the butylphthalide group was better than the traditional group, the differences were statistically significant (P<0.05). There was no significant difference in adverse reactions between the two groups (P>0.05).Conclusion Butylphthalide injection can im-prove the clinical efficacy of patients with acute progressive cerebral infarction, mainly by reducing hypercoagulability, antagonizing in-flammatory reaction, reducing homocysteine level, improving the expression level of nerve protein factors and other mechanisms. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
